ACELRX PHARMACEUTICALS INC	
Form 8-K	
October 12, 2017	

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 12, 2017

ACELRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE 001-35068 41-2193603 (State of incorporation) (Commission File No.) (IRS Employer Identification No.)


351 Galveston Drive

Redwood City, CA 94063

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (650) 216-3500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Item 2.02 Results of Operations and Financial Condition.

On October 12, 2017, AcelRx Pharmaceuticals, Inc. (the "Company" or "AcelRx") issued a press release that disclosed that the Company's estimated cash balance as of September 30, 2017 was \$67.9 million. The aforementioned financial information is included in the press release, as furnished in Exhibit 99.1 to this Current Report and is incorporated herein by reference.

Item 8.01 Other Events.

On October 12, 2017, the Company issued a press release entitled "AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIATM NDA," a copy of which is attached as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number Description

99.1 Press release dated October 12, 2017

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 12, 2017 $\stackrel{\hbox{\scriptsize ACELRX PHARMACEUTICALS}}{\hbox{\scriptsize INC.}}$

/s/ Jane By: Wright-Mitchell

Jane

Wright-Mitchell

Chief Legal Officer

EXHIBIT INDEX

Exhibit

Number Description

99.1 Press release dated October 12, 2017